Title: A Third Dose of SARS-CoV-2 Vaccine Increases Neutralizing Antibodies Against

Variants of Concern in Solid Organ Transplant Recipients

Authors: Andrew H. Karaba[1], Xianming Zhu[2], Tao Liang[1], Kristy H. Wang[1], Alex G.

Rittenhouse[1], Olivia Akinde[2], Yolanda Eby[2], Jessica E. Ruff[2], Joel N. Blankson[1], Aura T.

Abedon[3], Jennifer L. Alejo[3], Andrea L. Cox[1,4,5], Justin R. Bailey[1], Elizabeth A.

Thompson[1,5], Sabra L. Klein[1,4], Daniel S. Warren[3], Jacqueline M. Garonzik-Wang[6],

Brian J. Boyarsky[3], Ioannis Sitaras[4], Andrew Pekosz[1,4], Dorry L. Segev[3], Aaron A.R.

Tobian[2*], William A. Werbel[1*]

Affiliations:

[1]*Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.*
[2]*Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA*
[3]*Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.*
[4]*W. Harry Feinstone Department of Molecular Microbiology and Immunology, Johns Hopkins University*
Bloomberg School of Public Health, Baltimore, MD 21287, USA
[5]*Bloomberg Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University School of Medicine,*
Baltimore, MD 21287, USA.
[6]*Department of Surgery, University of Wisconsin School of Medicine and Health, Madison, WI 53792,*
USA
These authors contributed equally
20
21

22   **Corresponding author email:** wwerbel1@jhmi.edu

Abbreviations:

Anti-N: Anti-nucleocapsid antibody

Anti-RBD: Anti-Receptor Binding Domain antibody

Anti-S: Anti-Spike antibody

AU: Arbitrary Unit

AUC: Area Under the Curve

CFR: Case Fatality Rate

CM: Complete Media

ELISA: enzyme-linked immunosorbent assay

HC: Healthy Control

IM: Infection Media

MSD: Meso Scale Diagnostics

nAb: Neutralizing antibody

NT50: 50% Neutralization Titer

OD: Optical Density

SOTR: Solid Organ Transplant Recipient

TCID50: 50% Tissue Culture Infectious Dose

VOC: Variant of Concern

Word Count: 2,898

ABSTRACT:

Vaccine-induced SARS-CoV-2 antibody responses are attenuated in solid organ

transplant recipients (SOTRs) and breakthrough infections are more common.

Additional SARS-CoV-2 vaccine doses increase anti-spike IgG in some SOTRs, but it is

uncertain whether neutralization of variants of concern (VOCs) is enhanced. We tested

47 SOTRs for clinical and research anti-spike IgG, pseudoneutralization (ACE2

blocking), and live-virus neutralization (nAb) against VOCs before and after a third

SARS-CoV-2 vaccine dose (70% mRNA, 30% Ad26.COV2.S) with comparison to 15

healthy controls after two mRNA vaccine doses. We used correlation analysis to

compare anti-spike IgG assays and focused on thresholds associated with neutralizing

activity. A third SARS-CoV-2 vaccine dose increased median anti-spike (1.6-fold) and

receptor-binding domain (1.5-fold) IgG, as well as pseudoneutralization against VOCs

(2.5-fold versus Delta). However, IgG and neutralization activity were significantly lower

than healthy controls ($p < 0.001$); 32% of SOTRs had zero detectable nAb against Delta

after third vaccination. Correlation with nAb was seen at anti-spike IgG >4 AU on the

clinical assay and $>10^4$ AU on the research assay. These findings highlight benefits of

a third vaccine dose for some SOTRs and the need for alternative strategies to improve

protection in a significant subset of this population.

1. INTRODUCTION:

Solid organ transplant recipients (SOTRs) are at increased risk for severe COVID-19[1]. For example, while the case fatality rate (CFR) for the general population in the United States is 1-2%[2], CFRs range from 10-30% in SOTRs, due to a combination of chronic disease and immunosuppressive medications[3]. Therefore, effective and optimized vaccines that prevent COVID-19 disease in this group are critical. Unfortunately, these patients were excluded from the phase III trials of the mRNA based COVID-19 vaccines,[4,5] and recent publications suggest that breakthrough disease is more common among fully-vaccinated SOTRs than the general population[6,7]. Furthermore, it has been demonstrated that many SOTRs develop weak SARS-CoV-2 antibody responses after the recommended two doses of an mRNA-based vaccine[8–11]. This led to the hypothesis that a third dose of mRNA-based SARS-CoV-2 vaccine may improve the immune response to SARS-CoV-2 and protection from COVID-19. Although third doses have been authorized for immunocompromised persons in several countries, including the United States (US), published data on neutralizing capacity of SOTR plasma after additional vaccine doses are limited[12–14]. In particular, it is unknown if augmented immune responses to a third vaccine dose would result in protection against more transmissible variants of concern (VOCs) that exhibit immune escape, including the Delta variant which currently comprises >99% of new cases in the US[15]. In an effort to assess whether a third dose of SARS-CoV-2 vaccine in SOTRs would improve the SARS-CoV-2 specific neutralizing response, we measured total SARS-CoV-2 specific IgG and neutralizing activity against the vaccine strain and four VOCs before and after a third dose of SARS-CoV-2 vaccine and compared this to IgG levels

and neutralizing capacity of healthy controls who received a standard two-dose mRNA-

based vaccine series.

2. MATERIALS AND METHODS:

2.1 Cohorts:

SOTR participants were enrolled in a national prospective, observational cohort:

COVID-19 Antibody Testing of Recipients of Solid Organ Transplants and Patients with

Chronic Diseases, Johns Hopkins IRB00248540, as previously described[9,16]. Healthy

control participants were enrolled under Johns Hopkins IRB00027183[17]. SOTRs

submitted blood samples to the investigators 0-4 weeks before and 2 weeks after third

vaccine doses, which were independently obtained in the community. Blood was

collected in Acid Citrate Dextrose tubes and plasma was isolated by Ficoll centrifugation

and stored at -80°C.

2.2 IgG Measurement:

Plasma was tested using the clinically available EUROIMMUN anti-SARS-CoV-2

IgG enzyme-linked immunosorbent assay (ELISA) versus the S1 domain of spike

protein, performed per the manufacturers' protocols. Optical density (OD) of the sample

was divided by calibrator provided arbitrary unit (AU) ratio, for which ≥ 1.1 was

considered positive and ≥ 0.8–1.1 were considered indeterminate. Plasma was thawed

and anti-N, anti-RBD, and anti-S IgG was measured using the multiplex

chemiluminescent Meso Scale Diagnostics (MSD) V-PLEX COVID-19 Respiratory

Panel 3 Kit according to the manufactures' protocol at a dilution of 1:5000.

2.3 Pseudoneutralization/ACE2 Inhibition Measurement:

Plasma from study participants was thawed and ACE2 blocking was measured

using the ACE2 MSD V-PLEX SARS-CoV-2 Panel 6 and Panel 14 kits according to the

manufacturers' protocol at a dilution of 1:100.

2.4 Viruses and cells.

VeroE6-TMPRSS2 cells[18] were cultured in complete media (CM) consisting of

DMEM containing 10% FBS (Gibco, Thermo Fisher Scientific), 1 mM glutamine

(Invitrogen, Thermo Fisher Scientific), 1 mM sodium pyruvate (Invitrogen, Thermo

Fisher Scientific), 100 U/mL penicillin (Invitrogen, Thermo Fisher Scientific), and 100

µg/mL streptomycin (Invitrogen, Thermo Fisher Scientific). Cells were incubated in a 5%

CO_2 humidified incubator at 37°C.

The SARS-CoV-2/USA-WA1/2020 virus was obtained from BEI Resources. The

delta variant of SARS-CoV-2 (hCoV19/USA/MD-HP05660/2021, EPI_ISL_2331507)

was isolated on Vero-E6-TMPRSS2 cells plated in 24-well dishes and grown to 75%

confluence. The CM was removed and replaced with 150 µL of infection medium (IM),

which is identical to CM but with the fetal bovine serum reduced to 2.5%, and 150 ul of

the viral transport media containing a swab from a patient confirmed to be SARS-CoV-2

positive was added to the culture. The cultures were incubated at 37°C for 2 hours, the

inoculum was aspirated and replaced with 0.5 mL of IM and the cells cultured at 37°C

for up to 5 days. When a cytopathic effect was visible in most of the cells, the IM was

harvested and stored at –70°C. The presence of SARS-CoV-2 was verified by

extracting RNA from the harvested supernatant using the Qiagen Viral RNA extraction

kit (Qiagen), and viral RNA detected using quantitative RT-PCR.[19] The consensus

sequence of the virus isolate did not differ from the sequence derived from the clinical

specimen.

The infectious virus titer was determined on VeroE6-TMPRSS2 cells using a

50% tissue culture infectious dose (TCID50) assay as previously described for SARS-

CoV.[20,21] Serial 10-fold dilutions of the virus stock were made in IM, and then 100 µL of

each dilution was added to the cells in a 96-well plate in sextuplicate. The cells were

incubated at 37°C for 4 days, visualized by staining with naphthol blue-black, and

scored visually for cytopathic effect.

2.5 Neutralization assay.

The neutralizing antibody (nAb) levels were determined as described for SARS-

CoV.[22] Two-fold dilutions of plasma (starting at a 1:20 dilution) were made in IM.

Infectious virus was added to the plasma dilutions at a final concentration of 1 × 104

TCID50/mL (100 TCID50 per 100 µL). The samples were incubated for 1 hour at room

temperature, and then 100 µL of each dilution was added to 1 well of a 96-well plate of

VeroE6-TMPRSS2 cells in sextuplet for 6 hours at 37˚C. The inocula were removed,

fresh IM was added, and the plates were incubated at 37˚C for 2 days or until complete

cytopathic effect was visible in wells exposed to virus without plasma. The cells were

fixed by the addition of 100 µL of 4% formaldehyde per well, incubated for at least 4

hours at room temperature, and then stained with Napthol Blue Black (MilliporeSigma).

The nAb titer was calculated as the highest serum dilution that eliminated the cytopathic

effect in 50% of the wells and area under the curve (AUC) was calculated using

GraphPad Prism.

2.6 Statistical analysis:

Only SOTRs with available demographic and immunological data on pre and

post third dose of SARS-CoV-2 vaccine were included in the analysis. Wilcoxon signed

rank test was used to compare the median of SARS-CoV-2 anti-Spike and anti-RBD

IgG level and percent ACE2 inhibition before and after third dose of vaccine among

SOTRs. The median of IgG level and ACE2 inhibition between SOTRs and HCs were

compared using Wilcoxon rank sum test. Pearson correlation was used to evaluate the

linear association between Spike IgG and percent ACE2 inhibition among SOTRs. A

spline knot was added at 4 $\log_{10}$(AU) MSD IgG. Bonferroni correction was conducted to

control multiple comparison when analyzing variants (p<0.01 was considered

statistically significant). The analysis was also stratified by type of third dose vaccine,

age, sex, and graft transplanted to evaluate effect measure modification. Missing values

were treated using available case strategy in subgroup analysis.

3. RESULTS:

3.1 Pre- and post-third dose samples were available for 47 SOTRs followed in

our ongoing longitudinal observational cohort studying immunogenicity and safety of

SARS-CoV-2 vaccination. Most of these participants had previously undergone anti-

spike antibody testing using two clinically available assays[16]. The median age was 63

(interquartile range 49-70) years and 55% were female. Most SOTRs were kidney

transplant recipients (64%) and all initially received two doses of an mRNA-based

vaccine (23 Moderna mRNA-1273, 24 Pfizer BNT162b2). Most were taking a

calcineurin inhibitor-based maintenance immunosuppression regimen (77%) and 30%

were on "triple immunosuppression" with a calcineurin inhibitor, an antimetabolite, and

corticosteroids. 70% of SOTRs received a third mRNA vaccine dose and 30% received

the Janssen Ad26.COV2.S vaccine. None reported a known history of COVID-19.

Among mRNA-vaccinated healthy controls (HC, N=15), none had known medical

conditions, and all received two doses of BNT162b2. See **Table 1** for full demographic

and clinical data.

Anti-S1-Receptor binding domain (RBD), anti-Spike (S), and anti-Nucleocapsid

(N) total IgG were measured in plasma using a research assay (MSD) with FDA-verified

sero-positivity cutoffs before and after a third dose of SARS-CoV-2 vaccine in SOTRs

and after two doses of an mRNA-based vaccine in HCs. No participants had a positive

anti-N response at before or after a third dose of vaccine (**Supplemental Figure 1**).

Prior to a third dose of vaccine, 17 (36%) and 11 (23%) SOTRs were sero-positive for

anti-RBD and anti-S, respectively (**Figure 1A**). After the third dose, these numbers

increased to 36 (77%) and 34 (72%), respectively, and there was a significant increase

in the median total anti-S (1.6 fold change) and anti-RBD (1.5 fold change) IgG levels

compared to matched pre-third dose samples (**Figure 1A**). The median anti-RBD and

anti-S IgG values of SOTRs receiving a third dose remained significantly lower than the

median responses in fully vaccinated HCs after the two-dose series (**Figure 1B**). In

comparison to all other transplant recipients, kidney transplant recipients had

significantly lower anti-S IgG (**Figure 1C**). Eight (57%) of those receiving Ad26.COV2.S

as a third dose and 26 (79%) who received an mRNA-based vaccine as a third dose

became sero-positive. When stratifying by type of third dose received (mRNA versus

Ad.COV2.S), however, we did not observe a significant difference in median anti-S IgG

value (**Supplemental Figure 2C**). In exploratory analysis, median IgG levels did not

differ by other key clinical or demographic parameters such as age or sex, though

subgroup sizes were small (**Supplemental Figures 2A and 2B**). Notably, seven female

kidney recipients had the lowest post third dose IgG levels of all SOTRs in the study. All

were taking anti-metabolite maintenance immunosuppression, but they did not

otherwise share clinical or demographic factors.

3.2 Next, we investigated the neutralizing potential of SOTR plasma versus major

SARS-CoV-2 VOCs after three vaccine doses with comparison to that of healthy

individuals after two vaccine doses. This was assessed initially via an assay measuring

capacity of plasma to inhibit S protein binding to the ACE2 receptor, termed

pseudoneutralization. There was a significant increase in the median

pseudoneutralization of all variants after a third vaccine dose among SOTRs: fold

changes 2.5, 2.2, 1.6, 1.5, and 2.5 for vaccine, Alpha, Beta, Gamma, Delta variants,

respectively (**Figure 2A**). However, pseudoneutralization of all variants was significantly

lower than that of healthy controls after two doses of an mRNA-based vaccine (**Figure**

2B). For example, only two (6%) SOTRs had pseudoneutralization values for the Delta

variant above the first quartile of the healthy control pseudoneutralization values; the

majority were below 20% inhibition for all variants. When stratified by type of organ

received, kidney transplant recipients had significantly lower ACE2 inhibition versus the

vaccine strain and Alpha variant compared to all other organs (**Figure 2C**). Stratification

by age, sex, or vaccine platform, did not identify any significant differences in

pseudoneutralization (**Supplemental Figure 3**).

We also examined the correlation between anti-S IgG and pseudoneutralization

for all the variants. We found a strong correlation between anti-S IgG and

pseudoneutralization, but the relationship only became linear around 4 $\log_{10}$(arbitrary

unit, AU) IgG, suggesting that values below this may not correlate with neutralizing

response (**Figure 2D**).

3.3 Finally, we used live-virus neutralization (nAb) to assess 50% neutralization

titer (NT50) and area under the curve (AUC) against the vaccine strain and the Delta

variant before and after a third vaccine dose in SOTRs and in two-dose vaccinated

HCs. For SOTRs, median (IQR) NT50s were 40 (10-120) versus vaccine strain and 20

(10-40) versus Delta (**Figure 3A**), with median (IQR) AUC of 50 (2-145) and 9 (3-50),

respectively (**Figure 3B**) after a third vaccine dose. This corresponded to a fold change

in NT50 of 1.6 and 1.3 and a fold change in AUC 50.2 and 8.4 versus the vaccine strain

and Delta variant, respectively. Compared to HCs, NT50s and AUC versus vaccine and

Delta variant strains were significantly lower among SOTRs (**Figure 3D**). Fully 32% of

SOTRs had nAb NT50s at or below the limit of detection versus the Delta variant after a

third vaccine dose (as compared to 0% of HCs). There were two female liver transplant

recipients with very high neutralizing titers, even beyond those of the HCs.

3.4 We assessed inter-assay correlation for both the vaccine strain (**Figure 4A**)

and Delta variants (**Figure 4B**) among clinical (EUROIMMUN) and research (MSD) anti-

spike IgG assays, as well as pseudoneutralization and nAb AUC for SOTRs and HCs.

For the vaccine strain, EUROIMMUN and MSD IgG showed excellent positive

correlation, particularly above the clinical manufacturer threshold for seropositivity (1.1

AU). Correlation of pseudoneutralization with both IgG assays was strong above a

threshold of 20% ACE2 blocking. Below this, there was marked variation in

corresponding IgG levels among SOTRs (e.g., EUROIMMUN IgG ranged 0-7.5 AU)

(**Supplemental Figure 4**). Correlation of both IgG assays and nAb AUC was moderate,

though markedly improved when restricting to higher IgG cutoffs (4 AU on the

EUROIMMUN assay and 4 log10(AU) on the MSD assay). Overall correlation of

pseudoneutralization and nAb was stronger, particularly when restricting each to one

patient group (SOTR or HC). These cross-correlation patterns were similar when

considering the Delta variant, although pseudoneutralization and nAb AUC correlation

was overall stronger as compared to the vaccine strain, reflecting reduction in ACE2

blocking for HCs.

4. DISCUSSION

Here, we provide evidence that a third dose of COVID-19 vaccine increases

plasma neutralization against VOCs for some SOTRs, including versus the highly

transmissible and now dominant Delta variant. This was robustly characterized using a

combination of clinical and research IgG assays, pseudoneutralization, and gold-

standard live-virus neutralization. Although median plasma neutralizing capacity did

increase for SOTRs, levels were generally far below that of HCs after the two-dose

mRNA series and 32% showed no nAb against the Delta variant using the live-virus

assay.

Other key findings include lower neutralization among kidney transplant

recipients versus other transplant recipients, potentially reflecting heavier maintenance

immunosuppression. Other factors previously associated with improved sero-response

such as younger age or third dose vaccine platform (i.e., mRNA) were not clearly

associated with response. Importantly, although there was significant variability in IgG

responses in SOTRs, we found evidence through correlation analysis that certain IgG

cutoffs were associated with clear increases in ACE2 blocking, as well as in nAb. This is

an early step toward establishing thresholds for high-throughput assays that may

indicate protection from COVID-19, including the Delta variant, though this will need to

be tested by assessing risk of infection in real-world cohort and clinical trial settings.

The observed variable humoral response to additional vaccine doses in this high-

risk group indicates that alternative strategies, such as immunosuppressive modulation

or using emerging vaccine platforms, may be necessary to induce a protective response

to vaccination. While some SOTRs clearly produce an antibody response on par with

HCs, they were a small minority in this study. Though we identified kidney

transplantation as a risk factor for decreased responsiveness, the mechanism

underlying this association is unknown. This is evident in the seven female kidney

recipients who all had very low IgG and neutralizing responses, yet had no clear pattern

in demographic features, age, or vaccine platform received as a third dose. Additional

investigations and deeper immunological analyses are warranted to understand in a

personalized fashion why some SOTRs respond to additional antigen exposure, while

others do not.

This study was limited by its observational nature and small number of

participants with demographic and immunosuppressive heterogeneity. Additionally, HC

comparators were younger than the SOTR group, which may contribute to observed

differences in humoral response. Although patient survey and anti-N IgG were used to

rule out prior COVID-19, it is possible that subclinical infections occurred in some

patients before or after vaccination. Furthermore, mucosal immune responses and

cellular immune responses were not characterized in this study.

In summary, a third dose of a SARS-CoV-2 vaccine increases anti-spike and

anti-RBD IgG levels and plasma neutralizing capability, including against the Delta

variant, in some SOTRs. Yet, a significant portion of SOTRs have limited or no

neutralizing activity against the dominant VOC indicating that a third dose of vaccine

may not be a fully effective strategy for a large portion of immunocompromised patients.

These data also inform how research and clinical anti-spike IgG measurements might

be used to estimate neutralizing ability and potential sero-protection thresholds. This is

novel and timely information regarding the potential improvement of immune protection

against SARS-CoV-2 variants in a highly vulnerable population amidst ongoing

community surges.

ACKNOWLEDGEMENTS:

This work was supported by the Ben-Dov family, the Johns Hopkins COVID-19

Vaccine-related Research Fund, the National Cancer Institute (U54CA260491), grants

T32DK007713 (JLA), F32DK124941 (BJB), and K23DK115908 (JMGW) from the

National Institute of Diabetes and Digestive and Kidney Diseases, and grants

K24AI144954 (DLS), K08AI156021 (AHK), K23AI157893 (WAW),

HHSN272201400007C (AP) and R01AI120938S1 (AART) from the National Institute of

Allergy and Infectious Disease.

AUTHOR CONTRIBUTIONS:

AHK and WAW conceived of the study and design. OA, JER, and YE processed the

samples and prepared them for the assays. AHK, KHW, and AGR performed the MSD

assays and collected the antibody data. AP and IS performed the live virus

neutralization. ATA, JLA, JNB, DW, and BJB assisted with participant enrollment and

collection of clinical data. XZ and TL performed the analysis. EAT assisted with sample

curation and data interpretation. AHK and WAW wrote the original manuscript. JMG,

ALC, JNB, SLK, AP, JRB, DLS, AART, and WAW supervised the studies, provided

material support, and contributed to the interpretation of results. All authors aided in

editing the manuscript.

DISCLOSURES:

DLS has the following financial disclosures: consulting and speaking honoraria from

Sanofi, Novartis, CSL Behring, Jazz Pharmaceuticals, Veloxis, Mallinckrodt, Thermo

Fisher Scientific. None of the other authors have any relevant competing interests.

DATA AVAILABILITY:

Reasonable requests for deidentified data to the corresponding author will be granted.

 FIGURE LEGENDS

Figure 1. Changes in SARS-CoV-2 Specific IgG After a Third Dose of SARS-CoV-2

Vaccine

A. Total SARS-CoV-2 S1 RBD (left) and Spike (right) specific IgG in SOTRs before

and after a third dose of vaccine. The dashed line represents the assay

manufacturer's cut-off for seropositivity based on convalescent samples.

B. Total SARS-CoV-2 S1 RBD (left) and Spike (right) specific IgG in fully mRNA

vaccinated healthy controls (HCs) (n = 15) and SOTRs after a third dose of

vaccine (n = 47).

C. Total SARS-CoV-2 Spike specific IgG in SOTRs who received kidney (n = 30)

and non-kidney (n = 17) transplant.

364
365 The boxplots represent the IQR. The median is represented by a horizontal line in

366   the box. The lower and upper whiskers represent 1.5x the IQR beyond the quartiles.

367   Each dot represents an individual sample. Statistical differences between groups

368   were determined by Wilcoxon signed rank test for panel A, and Wilcoxon rank sum

369   test for panel B and C. P-values of <0.05 were considered significant.

Figure 2. SARS-CoV-2 Pseudoneutralization After a Third Dose of COVID-19 Vaccine in SOTRs

A. Pseudoneutralization of full-length SARS-CoV-2 Spike variants (indicated in top header of each panel) before and after a third dose of vaccine among SOTRs.

B. Pseudoneutralization of full-length SARS-CoV-2 Spike variants (indicated in top header of each panel) in SOTRs (n = 47) after a third dose of vaccine compared to fully vaccinated healthy controls (n = 15).

C. Comparison of pseudoneutralization of full-length SARS-CoV-2 Spike variants (indicated in top header of each panel) in SOTRs who received kidney (n = 30) and non-kidney (n = 17) transplant.

D. Correlation between total SARS-CoV-2 Spike IgG and pseudoneutralization of full-length SARS-CoV-2 Spike variants among SOTRs receiving a third dose of vaccine.

In panel A-C, the boxplots represent the IQR. The median is represented by a horizontal line in the box. The lower and upper whiskers represent 1.5x the IQR beyond the quartiles. Each dot represents an individual sample. Statistical differences between groups were determined by Wilcoxon signed rank test for panel A, and Wilcoxon rank sum test for panel B and C. Pearson correlation coefficient were generated for panel D. P-values of <0.01 were considered significant after Bonferroni correction.

Figure 3. Neutralizing antibody (nAb) versus SARS-CoV-2 vaccine strain and Delta variant

A. nAb NT50 versus SARS-CoV-2 vaccine strain and Delta variant before and after a third dose SARS-CoV-2 vaccine among SOTRs.

B. nAb area under curve (AUC) versus SARS-CoV-2 vaccine strain and Delta variant before and after a third dose SARS-CoV-2 vaccine among SOTRs.

C. Comparison of nAb reciprocal NT50 versus SARS-CoV-2 vaccine strain and Delta variant between SOTRs after a third dose of SARS-CoV-2 vaccine and HCs after two mRNA vaccine doses

D. Comparison of nAb AUC of SARS-CoV-2 vaccine strain and Delta variant between SOTRs after a third dose of SARS-CoV-2 vaccine and HCs after two mRNA vaccine doses.

In panel A-D, the boxplots represent the IQR. The median is represented by a horizontal line in the box. The lower and upper whiskers represent 1.5x the IQR beyond the quartiles. Each dot represents an individual sample. Statistical differences between groups were determined by Wilcoxon signed rank test for panel A and B, and Wilcoxon rank sum test for panel C and D.

Figure 4. Correlations between neutralizing antibody (nAb), percent ACE2 inhibition, MSD anti-spike IgG and EUROIMMUN anti-spike IgG of SARS-CoV-2 among SOTRs and HCs

A. Correlations between neutralizing and IgG assays versus the SARS-CoV-2 vaccine strain among SOTRs after a third dose of vaccine and HCs after two doses.

B. Correlations between neutralizing and IgG assays versus the Delta variant among SOTRs after a third dose of vaccine and HCs after two doses.

Each point on the scatter plots represents an individual sample. Pearson correlation coefficients between assays are presented in the upper panels. "Corr" represents the correlation across all samples. "HCs" (in red) represents the correlation among only HCs. "SOTR" (in blue) represents the correlation among only SOTRs. * $p < 0.05$; ** $p < 0.01$; *** $p < 0.001$. Density plots of SOTRs and HCs are shown in diagonal panels. Unit of analysis: nAb AUC, $\log_{10}$AUC; ACE2: percent ACE2 inhibition; MSD IgG, $\log_{10}$IgG AU/mL; EUROIMMUN IgG, AU/mL.

Table 1. Clinical and Demographic Characteristics of SOTRs and Healthy

Controls.

	Overall n = 62	SOTR n = 47	Healthy controls, n = 15
Age, years			
20-39	10 (16)	3 (6)	7 (47)
40-59	26 (42)	18 (38)	8 (53)
60-79	26 (42)	26 (55)	0 (0)
Sex			
Female	31 (50)	26 (55)	5 (33)
Male	31 (50)	21 (45)	10 (67)
Race			
White	57 (92)	46 (98)	11 (73)
Asian	4 (6)	1 (2)	3 (20)
African American	1 (2)	0 (0)	1 (7)
Graft transplanted			
Kidney*	-	30 (64)	-
Liver	-	10 (21)	-
Heart	-	4 (9)	-
Lung	-	2 (4)	-
Pancreas	-	1 (2)	-
Anti-rejection medication†			
Prednisone	-	22 (47)	-
Calcineurin Inhibitors	-	36 (77)	-
mTOR inhibitors	-	7 (15)	-
anti-metabolites	-	30 (64)	-
Type of the third dose vaccine			
mRNA	-	33 (70)‡	-
Ad26.COV2.S	-	14 (30)	-
Days between second dose and third dose vaccine	-	102 (70 - 124)	-
Days between transplant and third dose vaccine	-	1778 (930 - 4419)	-
Days post second dose vaccine	-	-	8 (7 – 10)

Note: all study participants received mRNA vaccine for the first two doses. Categorical variables were presented in n (%), and continuous variables were presented in median (interquartile range). *1 person had both kidney and pancreas transplanted and has been grouped into kidney category. †Anti-rejection medication use was not mutually exclusive. ‡10 (30%) of the 33 participants received a third mRNA vaccine that differed from their initial two-dose series.

Supplemental Figure 1.

Total SARS-CoV-2 Nucleocapsid specific IgG in SOTRs before and after a third dose of

vaccine. The dashed line represents the assay manufacturer's cut-off for positivity

based on convalescent samples. P-values were calculated using Wilcoxon rank sum

test.

Supplemental Figure 2.
454
Total SARS-CoV-2 Spike specific IgG in SOTRs who received a third dose of COVID-19

vaccine stratified by age (<60 n = 21 and ≥60 years n = 26), sex (female n = 26 and

male n = 21), and type of third dose vaccine received (mRNA n = 33 and Ad26.COV2.S

n = 14). P-values were calculated using Wilcoxon rank sum test and should be

considered exploratory given the small subgroups.

Supplemental Figure 3.

Pseudoneutralization of full-length SARS-CoV-2 Spike variants in SOTRs who received

a third dose of COVID-19 vaccine stratified by age (<60 n = 21 and ≥60 years n = 26),

sex (Female n = 26 and male n = 21), and type of third dose vaccine received (mRNA n

= 33 and Ad26.COV2.S n = 14). P-values were calculated using Wilcoxon rank sum test

and should be considered exploratory given the small subgroups.

Supplemental Figure 4. Correlation between percent ACE2 inhibition and

neutralizing antibody (nAb) and IgG of SARS-CoV-2 among SOTRs after a third

dose of COVID-19 vaccine, stratified by ACE2 inhibition level

A. Pearson correlation between vaccine strain percent ACE2 inhibition and vaccine

strain neutralizing antibody (nAb), MSD IgG and EUROIMMUN IgG of SARS-

CoV-2 among SOTRs after a third dose of COVID-19 vaccine.

B. Pearson correlation between Delta variant percent ACE2 inhibition and Delta

variant neutralizing antibody (nAb), MSD IgG and EUROIMMUN IgG of SARS-

CoV-2 among SOTRs after a third dose of COVID-19 vaccine.

Units of analysis: nAb AUC, $\log_{10}$AUC; ACE2: percent ACE2 inhibition; MSD IgG,

$\log_{10}$IgG AU/mL; EUROIMMUN IgG, AU/mL.

REFERENCES

1. Fung M, Babik JM. COVID-19 in Immunocompromised Hosts: What We Know So Far. *Clinical Infectious Diseases*. 2021;72(2):340-350. doi:10.1093/cid/ciaa863

2. COVID-19 Map. Johns Hopkins Coronavirus Resource Center. Accessed June 15, 2020. https://coronavirus.jhu.edu/map.html

3. Raja MA, Mendoza MA, Villavicencio A, et al. COVID-19 in solid organ transplant recipients: A systematic review and meta-analysis of current literature. *Transplantation Reviews*. 2021;35(1):100588. doi:10.1016/j.trre.2020.100588

4. Baden LR, El Sahly HM, Essink B, et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. *New England Journal of Medicine*. 2021;384(5):403-416. doi:10.1056/NEJMoa2035389

5. Polack FP, Thomas SJ, Kitchin N, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. *New England Journal of Medicine*. 2020;383(27):2603-2615. doi:10.1056/NEJMoa2034577

6. Aslam S, Adler E, Mekeel K, Little SJ. Clinical effectiveness of COVID-19 vaccination in solid organ transplant recipients. *Transplant Infectious Disease*. 2021;n/a(n/a):e13705. doi:10.1111/tid.13705

7. Qin CX, Moore LW, Anjan S, et al. Risk of Breakthrough SARS-CoV-2 Infections in Adult Transplant Recipients. *Transplantation*. Published online July 23, 2021. doi:10.1097/TP.0000000000003907

8. Boyarsky BJ, Werbel WA, Avery RK, et al. Immunogenicity of a Single Dose of SARS-CoV-2 Messenger RNA Vaccine in Solid Organ Transplant Recipients. *JAMA*. 2021;325(17):1784-1786. doi:10.1001/jama.2021.4385

9. Boyarsky BJ, Werbel WA, Avery RK, et al. Antibody Response to 2-Dose SARS-CoV-2 mRNA Vaccine Series in Solid Organ Transplant Recipients. *JAMA*. 2021;325(21):2204-2206. doi:10.1001/jama.2021.7489

10. Hall VG, Ferreira VH, Ierullo M, et al. Humoral and cellular immune response and safety of two-dose SARS-CoV-2 mRNA-1273 vaccine in solid organ transplant recipients. *American Journal of Transplantation*. 2021;n/a(n/a). doi:10.1111/ajt.16766

11. Sattler A, Schrezenmeier E, Weber UA, et al. Impaired humoral and cellular immunity after SARS-CoV2 BNT162b2 (Tozinameran) prime-boost vaccination in kidney transplant recipients. *J Clin Invest*. Published online June 8, 2021. doi:10.1172/JCI150175

12.   Hall VG, Ferreira VH, Ku T, et al. Randomized Trial of a Third Dose of mRNA-1273
Vaccine in Transplant Recipients. *N Engl J Med*. Published online August 11, 2021.
doi:10.1056/NEJMc2111462

13.   Kamar N, Abravanel F, Marion O, Couat C, Izopet J, Del Bello A. Three Doses of
an mRNA Covid-19 Vaccine in Solid-Organ Transplant Recipients. *New England*
Journal of Medicine. 2021;0(0):null. doi:10.1056/NEJMc2108861

14.   Benotmane I, Gautier G, Perrin P, et al. Antibody Response After a Third Dose of
the mRNA-1273 SARS-CoV-2 Vaccine in Kidney Transplant Recipients With
Minimal Serologic Response to 2 Doses. *JAMA*. 2021;326(11):1063.
doi:10.1001/jama.2021.12339

15.   CDC. COVID Data Tracker. Centers for Disease Control and Prevention. Published
March 28, 2020. Accessed August 6, 2021. https://covid.cdc.gov/covid-data-tracker

16.   Werbel WA, Boyarsky BJ, Ou MT, et al. Safety and Immunogenicity of a Third
Dose of SARS-CoV-2 Vaccine in Solid Organ Transplant Recipients: A Case
Series. *Ann Intern Med*. Published online June 15, 2021. doi:10.7326/L21-0282

17.   Woldemeskel BA, Karaba AH, Garliss CC, et al. The BNT162b2 mRNA Vaccine
Elicits Robust Humoral and Cellular Immune Responses in People Living with HIV.
Clinical Infectious Diseases. 2021;(ciab648). doi:10.1093/cid/ciab648

18.   Matsuyama S, Nao N, Shirato K, et al. Enhanced isolation of SARS-CoV-2 by
TMPRSS2-expressing cells. *Proc Natl Acad Sci USA*. 2020;117(13):7001.
doi:10.1073/pnas.2002589117

19.   Waggoner JJ, Stittleburg V, Pond R, et al. Triplex Real-Time RT-PCR for Severe
Acute Respiratory Syndrome Coronavirus 2. *Emerg Infect Dis*. 2020;26(7):1633-
1635. doi:10.3201/eid2607.201285

20.   Schaecher SR, Touchette E, Schriewer J, Buller RM, Pekosz A. Severe Acute
Respiratory Syndrome Coronavirus Gene 7 Products Contribute to Virus-Induced
Apoptosis. *Journal of Virology*. 2007;81(20):11054-11068. doi:10.1128/JVI.01266-
07

21.   Schaecher SR, Mackenzie JM, Pekosz A. The ORF7b Protein of Severe Acute
Respiratory Syndrome Coronavirus (SARS-CoV) Is Expressed in Virus-Infected
Cells and Incorporated into SARS-CoV Particles. *Journal of Virology*.
2007;81(2):718-731. doi:10.1128/JVI.01691-06

22.   Schaecher SR, Stabenow J, Oberle C, et al. An immunosuppressed Syrian golden
hamster model for SARS-CoV infection. *Virology*. 2008;380(2):312-321.
doi:10.1016/j.virol.2008.07.026